Day One Biopharmaceuticals Inc
Fermé
SecteurSoins de santé
21.45
Résumé
Variation du prix de l'action
24h
Min
Max
Revenu | -1.6M -21M |
|---|---|
Ventes | 14M 54M |
Marge bénéficiaire | -39.611 |
Employés | 178 |
EBITDA | -7.7M -26M |
Recommandations | Neutre |
|---|---|
Prévisions sur 12 Mois | -3.62% downside |
Capitalisation Boursière | 1B 2.2B |
|---|---|
Ouverture précédente | 21.45 |
Clôture précédente | 21.45 |
Sentiment de l'Actualité
By Acuity
50%
50%
166 / 342 Classement par Healthcare
Day One Biopharmaceuticals Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
